Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999308174> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W1999308174 endingPage "A56" @default.
- W1999308174 startingPage "A56" @default.
- W1999308174 abstract "Ventilator-associated pneumonia (VAP) is associated with increasing intensive care unit (ICU) admissions, morbidity and length of stay (LOS) as it's one of the most common nosocomial infections in the ICU; raising overall costs. Literature suggests costs could be significantly reduced by using the most efficient empiric therapy. The aim of this study was to assess the cost-effectiveness (CE) of linezolid against generic vancomycin as an empiric therapy for adult VAP patients, from the private health care perspective. A cohort of patients with VAP in the ICU was simulated using a decision-tree model to compare costs and effectiveness of linezolid (600 mg/12 hours) and vancomycin (15 mg/kg/12 hours) (basecase) over 10-28 days. Effectiveness measures were: clinical success rates, mortality rates, and hospital and ICU LOS. The model used a 12-week time horizon and only direct medical costs were considered (inpatient costs, medication expenses, adverse events costs, hematologic and gastrointestinal tests) Effectiveness and epidemiologic data were retrieved from published literature. Local costs (2011 US$) were gathered from Dominican Republic's capital's private hospital databases. Monte Carlo probabilistic sensitivity analysis (PSA) was constructed. Linezolid resulted as the most effective and less expensive option for VAP adult patients. Clinical success rate was higher with linezolid (64%) against vancomicyn (59.5%). Mean expected ICU LOS was 17.4 days for linezolid and 21.26 days for vancomycin; mean expected hospital LOS was 8.44 days versus 9.43 days, respectively. Mortality rate was found lower in the linezolid arm (10.13%) in comparison to vancomycin (15.74%). Overall costs per patient were $53,922.91 with linezolid and $67,437.44 with vancomycin. In the CE incremental analysis, linezolid appeared as the cost-saving option. PSA outcomes support the robustness of these findings. Linezolid resulted as the cost-saving therapy for treating VAP adult patients in ICU in the Dominican private clinical context." @default.
- W1999308174 created "2016-06-24" @default.
- W1999308174 creator A5007827388 @default.
- W1999308174 creator A5033002544 @default.
- W1999308174 creator A5075829906 @default.
- W1999308174 creator A5088916649 @default.
- W1999308174 date "2012-06-01" @default.
- W1999308174 modified "2023-10-17" @default.
- W1999308174 title "PRS25 Economic Evaluation of Linezolid Vs Vancomycin for Ventilator-Associated Pneumonia Patients in Private Hospitals of Dominican Republic" @default.
- W1999308174 doi "https://doi.org/10.1016/j.jval.2012.03.309" @default.
- W1999308174 hasPublicationYear "2012" @default.
- W1999308174 type Work @default.
- W1999308174 sameAs 1999308174 @default.
- W1999308174 citedByCount "0" @default.
- W1999308174 crossrefType "journal-article" @default.
- W1999308174 hasAuthorship W1999308174A5007827388 @default.
- W1999308174 hasAuthorship W1999308174A5033002544 @default.
- W1999308174 hasAuthorship W1999308174A5075829906 @default.
- W1999308174 hasAuthorship W1999308174A5088916649 @default.
- W1999308174 hasBestOaLocation W19993081741 @default.
- W1999308174 hasConcept C126322002 @default.
- W1999308174 hasConcept C177713679 @default.
- W1999308174 hasConcept C194828623 @default.
- W1999308174 hasConcept C197934379 @default.
- W1999308174 hasConcept C2776376669 @default.
- W1999308174 hasConcept C2777184939 @default.
- W1999308174 hasConcept C2777914695 @default.
- W1999308174 hasConcept C2778980435 @default.
- W1999308174 hasConcept C2779489039 @default.
- W1999308174 hasConcept C2781414143 @default.
- W1999308174 hasConcept C523546767 @default.
- W1999308174 hasConcept C54355233 @default.
- W1999308174 hasConcept C71924100 @default.
- W1999308174 hasConcept C86803240 @default.
- W1999308174 hasConceptScore W1999308174C126322002 @default.
- W1999308174 hasConceptScore W1999308174C177713679 @default.
- W1999308174 hasConceptScore W1999308174C194828623 @default.
- W1999308174 hasConceptScore W1999308174C197934379 @default.
- W1999308174 hasConceptScore W1999308174C2776376669 @default.
- W1999308174 hasConceptScore W1999308174C2777184939 @default.
- W1999308174 hasConceptScore W1999308174C2777914695 @default.
- W1999308174 hasConceptScore W1999308174C2778980435 @default.
- W1999308174 hasConceptScore W1999308174C2779489039 @default.
- W1999308174 hasConceptScore W1999308174C2781414143 @default.
- W1999308174 hasConceptScore W1999308174C523546767 @default.
- W1999308174 hasConceptScore W1999308174C54355233 @default.
- W1999308174 hasConceptScore W1999308174C71924100 @default.
- W1999308174 hasConceptScore W1999308174C86803240 @default.
- W1999308174 hasIssue "4" @default.
- W1999308174 hasLocation W19993081741 @default.
- W1999308174 hasOpenAccess W1999308174 @default.
- W1999308174 hasPrimaryLocation W19993081741 @default.
- W1999308174 hasRelatedWork W1966512214 @default.
- W1999308174 hasRelatedWork W1979883836 @default.
- W1999308174 hasRelatedWork W1986900569 @default.
- W1999308174 hasRelatedWork W1990710887 @default.
- W1999308174 hasRelatedWork W2009263326 @default.
- W1999308174 hasRelatedWork W2328497068 @default.
- W1999308174 hasRelatedWork W2580910213 @default.
- W1999308174 hasRelatedWork W2897142329 @default.
- W1999308174 hasRelatedWork W3030108261 @default.
- W1999308174 hasRelatedWork W81407855 @default.
- W1999308174 hasVolume "15" @default.
- W1999308174 isParatext "false" @default.
- W1999308174 isRetracted "false" @default.
- W1999308174 magId "1999308174" @default.
- W1999308174 workType "article" @default.